Kirkland Represents AbbVie on Acquisition of Allergan for $63 Billion

Kirkland & Ellis LLP advised AbbVie Inc. (NYSE: ABBV), a global, research-driven biopharmaceutical company, on its agreement to acquire Allergan plc (NYSE: AGN), a global pharmaceutical leader, in a cash and stock transaction for an equity value of approximately $63 billion. The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women’s health, eye care and virology. The transaction is subject to regulatory approvals and is expected to close in early 2020. 

Read the company press release

The Kirkland team was led by corporate partners Eric Schiele, Jonathan Davis and Carlo Zenkner and associate Lukas Richards; capital markets partners Sophia Hudson and Maggie Flores; debt finance partners Melissa Hutson and Yuli Wang; executive compensation partners Scott Price, Michael Krasnovsky and Kate Coverdale; antitrust partners Matt Reilly, Paula Riedel and Thomas Wilson; tax partners Dean Shulman, Sara Zablotney and Adam Kool; litigation partner Jim Hurst; and healthcare regulatory partner Dennis Williams.